Ferric Carboxymaltose/Dapagliflozin Propanediol Monohydrate

羧基麦芽糖铁/达格列净丙二醇一水化物

Report date: 2025/07/30 14:54:06

Base Information

Drug NameFerric Carboxymaltose/Dapagliflozin Propanediol Monohydrate
Drug Alias NameCombination of Iron Carboxymaltose and Dapagliflozin
ClassificationSmall molecules
Mechanisms of ActionSodium/glucose cotransporter 2 inhibitors
TargetsSodium/glucose cotransporter 2
Therapy Area/IndicationsIron deficiencyHeart Failure, Systolic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBrazil
CombinationsYes Ferric CarboxymaltoseDapagliflozin Propanediol Monohydrate
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesVifor Pharma
China Registration ClassN/A

Develop Information

Active CompaniesVifor Pharma
Inactive CompaniesN/A
Active IndicationsIron deficiencyHeart Failure, Systolic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A